CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.

Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.

He is a medical specialist in oncology-hematology, cancer cytogenetics, personalized cancer therapies, and clinical pharmacology, as well as an expert in biosciences, cancer research, drug design and development, and pharmacological innovations. He has authored multiple scientific publications in high-impact journals and received numerous citations for his work, focusing fully on experimental and clinical pharmacology and significantly advancing medical education and research in oncology and pharmacology. He has received several distinctions and grants from international research programs for his work. He holds degrees in Biology and Medicine, along with advanced postgraduate training.

This strategic engagement aligns with Cosmos Health's commitment to advancing groundbreaking therapeutics in oncology.

Professor Trafalis will lead research initiatives focusing on the design and execution of preclinical and clinical development strategies, regulatory support, and cutting-edge studies aimed at addressing critical oncology challenges. Specifically, his role includes overseeing preclinical and clinical protocols, making strategic decisions in research, and presenting key developments at global medical conferences and in international scientific journals.

Professor Trafalis stated: "I am excited to join Cosmos Health in its mission to advance oncology research and deliver life-changing treatments to patients worldwide, and I have great expectations for a high-performance collaboration. I truly believe that the project of Cosmos Health could serve the purpose of curing individuals with cancer in advanced stages. Together, we will focus on pioneering clinical strategies that address some of the most pressing challenges in cancer treatment today."

Greg Siokas, CEO of Cosmos Health, stated: "We are honored to welcome Professor Trafalis, a distinguished oncology leader, to spearhead our research initiatives. His expertise in clinical development will accelerate our efforts to address unmet medical needs and deliver transformative therapies to patients globally. We look forward to his invaluable contributions as we continue to build a robust oncology pipeline."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.